Search

Search Funnelback University

Search powered by Funnelback
Your query has been expanded to economic cost |d=2015 |u:www.enterprize.cam.ac.uk.  Search for economic cost |d=2015 |u:www.enterprise.cam.ac.uk instead.
1 - 10 of 11 search results for economic cost |d=2015 |u:www.enterprise.cam.ac.uk or economic cost |d=2015 |u:www.enterprize.cam.ac.uk where 3 match all words and 8 match some words.
  1. Fully-matching results

  2. CONSULTANCY CONTRACT

    https://www.enterprise.cam.ac.uk/wp-content/uploads/2011/09/ICM-Maintenance-Agreement.docx
    5 Aug 2015: revenue, goodwill, business opportunity or any indirect, consequential, financial or economic loss or damage, costs or expenses whether in contract, tort, negligence, breach of statutory duty or otherwise whatsoever or howsoever ... 8.5 The Client shall
  3. UK University Technology Transfer: behind the headlinesA note from ...

    https://www.enterprise.cam.ac.uk/wp-content/uploads/2015/05/behind-the-headlines.pdf
    8 May 2015: that benefit society and generate economic benefit for partners, universities, staff and students. ... Today, thanks to Solexa, a University of Cambridge spin-out from the Department of Chemistry, genome sequencing costs as little as $1,000 per genome.
  4. UK University Technology Transfer: behind the headlinesA note from ...

    https://www.enterprise.cam.ac.uk/wp-content/uploads/2015/04/Behind-the-headlines.pdf
    8 May 2015: that benefit society and generate economic benefit for partners, universities, staff and students. ... Today, thanks to Solexa, a University of Cambridge spin-out from the Department of Chemistry, genome sequencing costs as little as $1,000 per genome.
  5. Results that match 1 of 2 words

  6. Share and share alike: the cost of participation – Cambridge…

    https://www.enterprise.cam.ac.uk/share-and-share-alike-the-cost-of-participation/
    Thumbnail for Share and share alike: the cost of participation – Cambridge Enterprise 22 Dec 2015: Share and share alike: the cost of participation. Share:. Recently I wrote a blog post about my dislike of preference shares and how they dis-incentivise founders.
  7. Taking reagents to market – Cambridge Enterprise

    https://www.enterprise.cam.ac.uk/taking-reagents-to-market/
    Thumbnail for Taking reagents to market – Cambridge Enterprise 1 Dec 2015: are recompensed for the facility and consumables costs) or by working with external partners who have the capability to produce and/or store specialist reagents. ... Unlike the many other inventions we support at CE, reagents seldom involve the recovery
  8. Quethera: A new vision for gene therapy – Cambridge Enterprise

    https://www.enterprise.cam.ac.uk/blog-quethera-a-new-vision-for-gene-therapy/
    Thumbnail for Quethera: A new vision for gene therapy – Cambridge Enterprise 21 Sep 2015: Blindness has massive societal and healthcare-related impacts over and above any cost of treatment, so the greater-good argument should be enough to convince providers to pay. ... For example, rather than a huge upfront cost for a once-in-a-lifetime
  9. From Westminster to West Cambridge – Cambridge Enterprise

    https://www.enterprise.cam.ac.uk/from-westminster-to-west-cambridge/
    Thumbnail for From Westminster to West Cambridge – Cambridge Enterprise 15 Sep 2015: Most importantly though, I’ve found that at Cambridge Enterprise I’m again witness to activity that creates societal and economic impacts, this time through work that supports the transfer of
  10. Preferring to avoid preference shares - Cambridge Enterprise

    https://www.enterprise.cam.ac.uk/preferring-to-avoid-preference-shares/
    Thumbnail for Preferring to avoid preference shares - Cambridge Enterprise 14 Oct 2015: The founders are taking risks as well. Career, salary sacrifices, past sunk costs.
  11. Share and share alike: the maths behind the costs ...

    https://www.enterprise.cam.ac.uk/wp-content/uploads/2015/12/accompanying-docv4.docx
    22 Dec 2015: Share and share alike: the maths behind the costs of participation.
  12. Technology transfer: vital support or roadblock to commercialisation? …

    https://www.enterprise.cam.ac.uk/technology-transfer-vital-support-or-roadblock-to-commercialisation/
    Thumbnail for Technology transfer: vital support or roadblock to commercialisation? – Cambridge Enterprise 12 May 2015: Today, thanks to University spin-out Solexa, from the Department of Chemistry, and £100k in seed Fund investment from Cambridge Enterprise, genome sequencing costs as little as $1,000 per genome.

Refine your results

Format

Date

Search history

Recently clicked results

Recently clicked results

Your click history is empty.

Recent searches

Recent searches

Your search history is empty.